Michaelson Jennifer sold $608K of CGEM
Michaelson Jennifer (Chief Scientific Officer) sold 30,000 shares of Cullinan Therapeutics, Inc. (CGEM) at $20.26 ($0.61M total) on 2026-08-13 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the CSO’s sale details (30,000 shares at $20.2600) and that it was executed under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor insider activity for sentiment, but this specific disclosure lacks fundamental catalysts.
What to watch
The filing does not indicate whether other insiders or the company have concurrent news; without that, the signal is mostly sentiment.
Background
The article is a SEC Form 4 insider transaction disclosure for Cullinan Therapeutics, Inc.
Ticker impact
Cullinan Therapeutics CSO Jennifer Michaelson filed a Form 4 selling 30,000 shares at $20.2600 on 2026-08-13 under a 10b5-1 plan.
Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.
The filing discloses transaction size and price, but provides no new company fundamentals, guidance, or regulatory/operational catalyst.
Market effects
No clear sector read-through from a single 10b5-1 insider sale.
None indicated.
None indicated.
Counterpoint
10b5-1 sales can reflect routine liquidity planning rather than bearish expectations, so the market may ignore it.
Key entities
- issuerCullinan Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderJennifer Michaelson
Chief Scientific Officer who sold shares.
